M PAUL HENRI CONSIGNY

Rhumatologue

📍 PARIS CEDEX 15 (75)SalariéRPPS 10001453355

📊 Reconnaissance scientifique : 20/100📝 99 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Profil synthétique

IA · 19/05/2026

Le Dr Paul Henri Consigny est un rhumatologue salarié à Paris, avec une production scientifique significative dans le domaine des maladies infectieuses et de la santé liée aux voyages. Son h-index de 20 et ses 99 publications reflètent son engagement dans la recherche. Ses travaux portent notamment sur l'épidémiologie, la corticothérapie et la pharmacovigilance.

Expertises présumées

Épidémiologie des maladies infectieuses
Corticothérapie
Pharmacovigilance
Maladies à transmission vectorielle
Recherche sur le paludisme
Recherche sur le VIH
Santé des voyageurs

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa

Dermatology (Basel, Switzerland) · 2011

📚 103 citations🎯 RCR 4.21Top 10% NIH

Lire l'abstract Crossref ↓

Background: Antibiotics have been shown to improve hidradenitis suppurativa (HS) patients but complete remission is rare using these treatments. Objective: To assess the efficacy and safety of a combination of oral rifampin, moxifloxacin and metronidazole in long-lasting refractory HS. Methods: We retrospectively studied 28 consecutive HS patients including 6, 10 and 12 Hurley stage 1, 2 and 3 patients, respectively. Complete remission, defined as a clearance of all inflammatory lesions including hypertrophic scars, was the main outcome criterion of the study. Results: Complete remission was obtained in 16 patients, including 6/6, 8/10 and 2/12 patients with Hurley stage 1, 2 and 3, respectively (p = 0.0004). The median duration of treatment to obtain complete remission was 2.4 (range 0.9–6.5) and 3.8 months (range 1.6–7.4) in stage 1 and 2 patients, respectively, and 6.2 and 12 months in the 2 stage 3 patients. Main adverse events of the treatments were gastrointestinal disorders (64% of patients) and vaginal candidiasis (35% of females). Reversible tendinopathy and hepatitis occurred in 4 and 1 patient, respectively. Conclusions: Complete remission of refractory HS can be obtained using broad-spectrum antibiotics and Hurley staging is a prognostic factor of response to the treatment.

Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study

Arthritis care & research · 2013

📚 29 citations🎯 RCR 1.11

Lire l'abstract Crossref ↓

ObjectiveTo assess the safety and immunogenicity of live attenuated yellow fever (YF) 17D vaccine in adults receiving systemic corticosteroid therapy.MethodsAll adult travelers on systemic corticosteroid therapy who had received the YF17D vaccine in 24 French vaccination centers were prospectively enrolled and matched with healthy controls (1:2) on age and history of YF17D immunization. Safety was assessed in a self‐administered standardized questionnaire within 10 days after immunization. YF‐specific neutralizing antibody titers were measured 6 months after vaccination in patients receiving corticosteroids.ResultsBetween July 2008 and February 2011, 102 vaccine recipients completed the safety study (34 receiving corticosteroids and 68 controls). The median age was 54.9 years (interquartile range [IQR] 45.1–60.3 years) and 45 participants had a history of previous YF17D immunization. The median time receiving corticosteroid therapy was 10 months (IQR 1–67 months) and the prednisone or equivalent dosage was 7 mg/day (IQR 5–20). Main indications were autoimmune diseases (n = 14), rheumatoid arthritis (n = 9), and upper respiratory tract infections (n = 8). No serious adverse event was reported; however, patients receiving corticosteroids reported more frequent moderate/severe local reactions than controls (12% and 2%, respectively; relative risk 8.0, 95% confidence interval 1.4–45.9). All subjects receiving corticosteroids who were tested (n = 20) had neutralizing antibody titers >10 after vaccination.ConclusionAfter YF17D immunization, moderate/severe local reactions may be more frequent in patients receiving systemic corticosteroid therapy. Immunogenicity seems satisfactory. Large‐scale studies are needed to confirm these results.

Fungal infections in immunocompromised travelers

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013

📚 27 citations🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M PAUL HENRI CONSIGNY

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (14) — classées par pathologie

Transversal12

Épidémiologie & registres2

Corticothérapie1

Pharmacovigilance1

Partager cette fiche